Published in Br J Clin Pharmacol on October 01, 1987
A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. PLoS One (2014) 0.78
Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol (1989) 0.76
Safety of propranolol in portal hypertension. Conventional and long acting formulations. Drugs (1989) 0.75
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods (1983) 4.64
The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol (1978) 2.68
Propranolol--a medical treatment for portal hypertension? Lancet (1980) 2.27
Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis (1977) 2.15
A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol (1976) 1.87
Clinical pharmacokinetics of propranolol. Clin Pharmacokinet (1979) 1.81
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Criteria for selection of patients for emergency portacaval shunt. Am J Surg (1977) 1.33
Fibreoptic endoscopy and the use of the Sengstaken tube in acute gastrointestinal haemorrhage in patients with portal hypertension and varices. Gut (1976) 1.29
The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet (1979) 1.28
Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology (1981) 1.25
Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut (1985) 1.07
Propranolol in decompensated alcoholic cirrhosis. Lancet (1982) 1.01
The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration. Br J Clin Pharmacol (1981) 0.94
Influence of age and smoking on drug kinetics in man: studies using model compounds. Clin Pharmacokinet (1980) 0.85
Cirrhosis, hepatic encephalopathy, and propranolol. Br Med J (Clin Res Ed) (1983) 0.79
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother (1965) 4.71
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
The pharmacology of beta sympathetic blockade. Am J Cardiol (1966) 3.96
Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia (1992) 3.43
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Optical isomers of propranolol. Nature (1966) 3.09
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Br J Pharmacol Chemother (1966) 2.52
Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 2.33
Is cyclic vomiting syndrome related to migraine? J Pediatr (1999) 2.24
The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol (1972) 2.11
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
Salivary excretion of paracetamol in man. J Pharm Pharmacol (1973) 1.93
National Poisons Information Services: report and comment 1980. Br Med J (Clin Res Ed) (1981) 1.91
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br J Pharmacol (1970) 1.81
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother (1989) 1.76
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (1966) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc Res (1967) 1.61
Neonatal thyrotoxicosis treated with propranolol. Arch Dis Child (1974) 1.59
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol (1980) 1.57
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Stimulation of adrenergic beta-receptors by orciprenaline. Br Med J (1967) 1.52
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
A comparison of peripheral vasoconstrictor responses and cardiovascular autonomic function tests in diabetic patients. Diabetologia (1990) 1.45
Effect of dental treatment on the lung function of children with asthma. J Am Dent Assoc (1998) 1.42
Clinical pharmacology methodology: introduction. Br J Clin Pharmacol (1978) 1.39
Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol (1971) 1.37
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol (1973) 1.36
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol (1982) 1.32
Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet (1968) 1.29
Characterization of Tn1546 in vancomycin-resistant Enterococcus faecium isolated from canine urinary tract infections: evidence of gene exchange between human and animal enterococci. J Clin Microbiol (2002) 1.27
Stimulation of gastrin release by catecholamines. Lancet (1972) 1.26
Comparison of the effects of propranolol and MJ 1999 on cardiac beta-adrenoceptors in man. Br J Pharmacol (1970) 1.24
Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Clin Pharmacol Ther (1981) 1.23
Use of PCR primers containing a 3'-terminal ribose residue to prevent cross-contamination of amplified sequences. Nucleic Acids Res (1993) 1.21
The role of aflatoxin metabolism in its toxic lesion. Toxicol Appl Pharmacol (1976) 1.18
Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. Br J Pharmacol (1988) 1.17
Bone mass in healthy children: measurement with quantitative DXA. Radiology (1991) 1.17
Role of nutrition in the drug-metabolizing enzyme system. Pharmacol Rev (1974) 1.16
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man. Br J Clin Pharmacol (1983) 1.16
Oral candidal carriage and infection in insulin-treated diabetic patients. Diabet Med (1999) 1.15
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Is verapamil a beta-blocker? Lancet (1968) 1.11
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
Chemical and biological studies of a cigarette that heats rather than burns tobacco. J Clin Pharmacol (1990) 1.10
The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J (1977) 1.09
Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. Diabetes Care (1994) 1.09
Isolation of C. dubliniensis from insulin-using diabetes mellitus patients. J Oral Pathol Med (2000) 1.09
Hypergastrinaemia in rheumatoid arthritis: disease or iatrogenesis. Br Med J (1973) 1.08
The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol (1982) 1.08
Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia (1993) 1.06
Compression of the deep palmar branch of the ulnar nerve. Case report and anatomical study. J Bone Joint Surg Br (1969) 1.06
Alinidine reduces heart-rate without blockade of beta-adrenoceptors. Lancet (1981) 1.06
Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharmacol (1971) 1.04
Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol (1988) 1.03
The effect of age and cardiac failure on xamoterol pharmacokinetics. Br J Clin Pharmacol (1988) 1.02
The effects of laser irradiation on the central nervous system. I. Preliminary studies. J Neuropathol Exp Neurol (1967) 1.01
Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1986) 1.01
The effect of the dextro isomer of propranolol on sinus rate and cardiac arrhythmias. Am Heart J (1968) 1.01
Motor vehicle driving among diabetics taking insulin and non-diabetics. BMJ (1989) 1.00
The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551. J Cardiovasc Pharmacol (1988) 1.00
Comparison of the effects of isoprenaline, orciprenaline, salbutamol and isoetharine on the cardiovascular system of anaesthetized dogs. Br J Pharmacol (1971) 1.00
The properties of beta-adrenoceptor antagonists. Postgrad Med J (1976) 1.00
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Lasers and their neurosurgical application. Mil Med (1966) 0.99
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug. J Cardiovasc Pharmacol (1985) 0.98
Pulmonary involvement in ulcerative colitis. Br J Dis Chest (1988) 0.97
Mexiletine in normal volunteers. Br J Clin Pharmacol (1978) 0.97
Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure. Eur J Clin Pharmacol (1988) 0.97
A comparison of the cardiovascular actions of four adrenergic -receptor blocking agents in resting, conscious dogs. Am Heart J (1971) 0.97
Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA). Br J Clin Pharmacol (1981) 0.96
Studies of the nephrotoxicity of ethylenediaminetetraacetic acid. Biochem Pharmacol (1966) 0.96
Prevalence of streptogramin resistance genes among Enterococcus isolates recovered from retail meats in the Greater Washington DC area. J Antimicrob Chemother (2002) 0.95
Depression in medical in-patients. Br J Med Psychol (1988) 0.94
Revising the Seriousness of Illness Rating Scale: modernization and re-standardization. Int J Psychiatry Med (1987) 0.94
Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol (1982) 0.94
Effects of laser irradiation on the central nervous system. II. The intracranial explosion. J Neurol Neurosurg Psychiatry (1968) 0.93
Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol (1999) 0.92
Differentiating cyclic from chronic vomiting patterns in children: quantitative criteria and diagnostic implications. Pediatrics (1996) 0.92
Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. Clin Pharmacokinet (1987) 0.90
Retina: pathology of neodymium and ruby laser burns. Science (1965) 0.89
Studies of the agonist and antagonist activity of cicloprolol in man. Eur J Clin Pharmacol (1988) 0.89
Inhibition of the carotid sinus reflex by the chronic administration of propranolol. Br J Pharmacol (1969) 0.89
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs (1987) 0.89
Heterogeneity of diagnoses presenting as cyclic vomiting. Pediatrics (1998) 0.88
Incidence of orthostatic hypotension in patients with primary affective disorders treated with tricyclic antidepressants. Mayo Clin Proc (1977) 0.88